41 results on '"Friberg, Lena E."'
Search Results
2. Quantitative modeling of tumor dynamics and development of drug resistance in non‐small cell lung cancer patients treated with erlotinib
3. A model‐based approach leveraging in vitro data to support dose selection from the outset: A framework for bispecific antibodies in immuno‐oncology
4. Model‐based assessment of neutrophil‐mediated phagocytosis and digestion of bacteria across in vitro and in vivo studies
5. Assessment of ibrutinib scheduling on leukocyte, lymph node size and blood pressure dynamics in chronic lymphocytic leukemia through pharmacokinetic‐pharmacodynamic models
6. A multistate modeling and simulation framework to learn dose–response of oncology drugs: Application to bintrafusp alfa in non‐small cell lung cancer
7. Multistate Pharmacometric Model to Define the Impact of Second‐Line Immunotherapies on the Survival Outcome of the IMpower131 Study
8. Rituximab pharmacokinetic and pharmacokinetic–pharmacodynamic evaluation based on a study in diffuse large B‐cell lymphoma: Influence of tumor size on pharmacokinetic and assessment of pharmacokinetic similarity
9. Optimization of blood pressure measurement practices for pharmacodynamic analyses of tyrosine‐kinase inhibitors
10. Bayesian forecasting of tumor size metrics and overall survival
11. Population Pharmacokinetics and Exposure‐Response Relationships of Astegolimab in Patients With Severe Asthma
12. Continuous infusion of piperacillin‐tazobactam significantly improves target attainment in children with cancer and fever
13. Multistate model for pharmacometric analyses of overall survival in HER2‐negative breast cancer patients treated with docetaxel
14. CPT: Pharmacometrics & Systems Pharmacology – Inception, Maturation, and Future Vision
15. Dr. Hartmut Derendorf, PhD, a world‐renowned expert in pharmacokinetics and pharmacometrics (1953–2020)
16. Tumor growth inhibition modeling of individual lesion dynamics and interorgan variability in HER2‐negative breast cancer patients treated with docetaxel
17. Model‐Informed Drug Development for Anti‐Infectives: State of the Art and Future
18. Pivotal Role of Translation in Anti‐Infective Development
19. Model‐Informed Drug Development for Antimicrobials: Translational PK and PK/PD Modeling to Predict an Efficacious Human Dose for Apramycin
20. Tumor Time‐Course Predicts Overall Survival in Non‐Small Cell Lung Cancer Patients Treated with Atezolizumab: Dependency on Follow‐Up Time
21. Pharmacometrics and Systems Pharmacology 2030
22. Effects of cladribine tablets on heart rate, atrio‐ventricular conduction and cardiac repolarization in patients with relapsing multiple sclerosis
23. Piperacillin pharmacokinetics and target attainment in children with cancer and fever: Can we optimize our dosing strategy?
24. A PK/PD Analysis of Circulating Biomarkers and Their Relationship to Tumor Response in Atezolizumab‐Treated non‐small Cell Lung Cancer Patients
25. A Whole-Body Physiologically Based Pharmacokinetic Model for Colistin and Colistin Methanesulfonate in Rat
26. The risk of febrile neutropenia in breast cancer patients following adjuvant chemotherapy is predicted by the time course of interleukin-6 and C-reactive protein by modelling
27. Models for change in tumour size, appearance of new lesions and survival probability in patients with advanced epithelial ovarian cancer
28. Population pharmacokinetic–pharmacodynamic modelling in oncology: a tool for predicting clinical response
29. Characterizing variability in warfarin dose requirements in children using modelling and simulation
30. Comparison of the agonist-antagonist interaction model and the pool model for the effect of remoxipride on prolactin
31. A Semi‐Mechanistic Model of CP‐690,550‐Induced Reduction in Neutrophil Counts in Patients With Rheumatoid Arthritis
32. Model-Based Neutrophil-Guided Dose Adaptation in Chemotherapy: Evaluation of Predicted Outcome with Different Types and Amounts of Information
33. Pharmacokinetic-pharmacodynamic modelling of QT interval prolongation following citalopram overdoses
34. Pharmacokinetic/Pharmacodynamic Modelling in Oncological Drug Development
35. Pharmacodynamic differences between species exemplified by the novel anticancer agent CHS 828
36. Multistate modeling for survival analysis in critically ill patients treated with meropenem.
37. Rituximab pharmacokinetic and pharmacokinetic-pharmacodynamic evaluation based on a study in diffuse large B-cell lymphoma: Influence of tumor size on pharmacokinetic and assessment of pharmacokinetic similarity.
38. Model-Informed Drug Development for Antimicrobials: Translational PK and PK/PD Modeling to Predict an Efficacious Human Dose for Apramycin.
39. From Therapeutic Drug Monitoring to Model-Informed Precision Dosing for Antibiotics.
40. Pharmacometrics and Systems Pharmacology 2030.
41. A PK/PD Analysis of Circulating Biomarkers and Their Relationship to Tumor Response in Atezolizumab-Treated non-small Cell Lung Cancer Patients.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.